- Home
- IPXG vs AMRN Comparison
IPXG vs AMRN Comparison
Compare IPXG & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IPXG | AMRN |
|---|---|---|
| Founded | 2025 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.7M | 287.9M |
| IPO Year | 2026 | 1998 |
Fundamental Metrics
Financial Performance| Metric | IPXG | AMRN |
|---|---|---|
| Price | $10.11 | $11.27 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 137.1K | 57.2K |
| Earning Date | 11-20-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $10.03 | $11.34 |
| 52 Week High | $10.12 | $20.90 |
Technical Indicators
Market Signals| Indicator | IPXG | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 18.14 |
| Support Level | $10.03 | N/A |
| Resistance Level | N/A | $15.34 |
| Average True Range (ATR) | 0.01 | 0.35 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 87.13 | 3.20 |
Price Performance
Historical ComparisonAbout IPXG Inflection Point Acquisition Corp. VII Class A Ordinary Shares
Inflection Point Acquisition Corp VII is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.